Geron Stock Hits New 52-Week Low (GERN)

NEW YORK ( TheStreet) -- Geron Corporation (Nasdaq: GERN) hit a new 52-week low Monday as it is currently trading at $2.02, below its previous 52-week low of $2.05 with 1.3 million shares traded as of 2:50 p.m. ET. Average volume has been 1.7 million shares over the past 30 days.

Geron has a market cap of $283.8 million and is part of the health care sector and drugs industry. Shares are down 59.1% year to date as of the close of trading on Friday.

Geron Corporation, a biopharmaceutical company, develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes.
  • Practice your GERN trading strategies and win cash in our stock game.

TheStreet Ratings rates Geron as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. You can view the full Geron Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

null

More from Markets

Amazon's Big Weakness in the Supreme Court Sales Tax Ruling

Amazon's Big Weakness in the Supreme Court Sales Tax Ruling

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Tesla's Automotive Gross Margins May Be Overstated, Analysts Suggest

Tesla's Automotive Gross Margins May Be Overstated, Analysts Suggest

Dow Rises for First Time in 9 Days, Oil Soars as OPEC Agrees to Boost Output

Dow Rises for First Time in 9 Days, Oil Soars as OPEC Agrees to Boost Output

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices

OPEC Deal Doesn't Boost Production Enough to Drive Down Crude, Gasoline Prices